Author: Dzmitry Korsak

The Japanese startup Integral AI has announced that it has created the “world’s first AGI-capable model.” According to a company representative, the team has achieved one of the ultimate goals of artificial intelligence development: enabling their AI model to learn new tasks “without pre-existing datasets or human intervention.”

Doctorina has arrived on Telegram — and it looks like one of the first notable cases of a specialized medical LLM stepping out of the…

American shoppers once again staged a record shopping marathon: according to Adobe Analytics, they spent $11.8 billion online on Black Friday 2025, 9.1% more than a year earlier. Globally, analysts put total online Black Friday sales at around $78–80 billion — and a substantial share of that pie now comes from European consumers hunting for discounts and increasingly turning to AI to help them choose what to buy.

In 2025, millions of people share the same experience: you ask an AI a perfectly reasonable question – and in response you either get confident nonsense or a polite refusal that reads like a lazy “please go away”. At the same time, the very same AI writes code brilliantly, helps draft contracts, and turns forty-page reports into summaries in seconds.

We trust fitness trackers to count our steps and calories, but can we trust a smartphone or watch with our sleep? It turns out, yes, provided we are talking about apps that have undergone clinical trials and received medical approval. Let’s look at three digital solutions that go beyond collecting data to actually diagnosing and treating sleep disorders.

Femtech is booming. According to FemTech Analytics, the sector is on track https://www.femtech.health/interactive-charts to reach $75.1 billion by 2025. Yet there’s also a “silent” potential worth $360 billion — an invisible market still untouched by today’s industry. Flo has long been a femtech synonym, but once you set aside that “obligatory first line,” you’ll find plenty of robust, evidence-based, and, crucially, battle-tested alternatives. Here are three apps we think deserve your attention.

The gaming industry ceased to be something unserious or just for children long ago. It is a huge market with pharma-level budgets, top-tier development teams, advanced R&D units, and extremely fine-tuned work with human attention, motivation, and behavior. It is only logical that medicine is looking more and more in this direction – if games can keep people engaged for hours, why not use the same mechanics when a patient needs help getting through treatment, rehabilitation, or complex learning?

As the year draws to a close, major analytics firms traditionally share their view on where the medtech industry is heading and what to expect in the near future. We have gone through these reports and distilled the essentials: from the explosive growth of AI in medical devices and the portable tech market to regional regulatory specifics and shifting investment priorities. This article brings together the key figures, insights, and directions that will shape medtech over the coming years.

Another unusual “side effect” has been observed with semaglutide — the drug better known as Ozempic and Wegovy. Originally developed for type 2 diabetes, it proved effective for weight reduction, and now appears to benefit treatment of certain cancers. A University of California San Diego study reports that among people with colon cancer who were concurrently taking semaglutide, five-year mortality was 15.5%, whereas among those not taking it the figure was 37.1% — more than twice as high.

AI now shows up in everyday mental-health chats—from sleep tips to suicidal disclosures—driven by poor access, stigma, and the lure of anonymous, free help. Yet LLMs are unreliable: they err, lose context, miss non-verbal cues, and can reinforce distortions. Crisis-performance evidence is thin, and the red lines remain contested.